Ranolazine, a novel anti-anginal agent, does not alter isosorbide dinitrate- or sildenafil-induced changes in blood pressure in conscious dogs

European Journal of Pharmacology

Volumn 541, Issue 3, 2006, Pages 171-176

  Zhao, Gong ^a   Messina, Eric ^b   Xu, Xiaobin ^b   Ochoa, Manuel ^b   Serpillon, Sobrina ^b   Shryock, John ^a   Belardinelli, Luiz ^a   Hintze, Thomas H ^b  

^a CV THERAPEUTICS INC   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Blood pressure; Conscious dog; Heart rate; Long acting nitrate; Ranolazine; Sildenafil

Indexed keywords

ANTIANGINA PECTORIS AGENT; ISOSORBIDE DINITRATE; RANOLAZINE; SILDENAFIL;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOG; DOSE RESPONSE; HEART RATE; HYPOTENSION; MALE; MEAN ARTERIAL PRESSURE; MEASUREMENT; NONHUMAN; PRIORITY JOURNAL; TACHYCARDIA;

ANGINA PECTORIS; ANIMALS; BLOOD PRESSURE; DOGS; ENZYME INHIBITORS; HEART RATE; HYPOTENSION; INJECTIONS, INTRAVENOUS; ISOSORBIDE DINITRATE; MALE; PIPERAZINES; STIMULATION, CHEMICAL; VASODILATOR AGENTS;

EID: 33745124037     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.05.016     Document Type: Article

References (20)

1. Antzelevitch C., Belardinelli L., Zygmunt A.C., Burashnikov A., Di Diego J.M., Fish J.M., Cordeiro J.M., and Thomas J. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 110 (2004) 904-910
2. Chaitman B.R. Efficacy and safety of a metabolic modulator drug in chronic stable angina: review of evidence from clinical trials. J. Cardiovas. Pharmacol. Ther. 9 Suppl I (2004) S47-S64
3. Chaitman B.R., Pepine C.J., Parker J.O., Skopal J., Chumakoya G., Kuch J., Wang W., Skettino S.L., and Wolff A.A. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. J. Am. Med. Assoc. 291 (2004) 309-316
4. Chaitman B.R., Skettino S.L., Parker J.O., Hanley P., Meluzin J., Kuch J., Pepine C.J., Wang W., Nelson J., Hebert D.A., and Wolff A.A. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J. Am. Coll. Cardiol. 43 (2004) 1375-1382
5. Chen J.-S., Wang W., Cornish K.G., and Zucker I.H. Baro- and ventricular reflexes in conscious dogs subjected to chronic tachycardia. Am. J. Physiol. 263 (1992) H1084-H1089
6. Gibbons R.J., Abrams J., Chatterjee K., Daley J., Deedwania P.C., Douglas J.S., et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients with Chronic Stable Angina). J. Am. Coll. Cardiol. 41 (2003) 159-168
7. Gori T., Floras J.S., and Parker J.D. Effects of nitroglycerin treatment on baroreflex sensitivity and short-term heart rate variability in humans. J. Am. Coll. Cardiol. 40 (2002) 2000-2005
8. Heidenreich P.A., McDonald K.M., Hastie T., Fadel B., Hagan V., Lee B.K., and Mark A. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA 281 (1999) 1927-1936
9. Jackson G. Treatment of erectile dysfunction in patients with cardiovascular disease: guide to drug selection. Drugs 64 (2004) 1533-1545
10. Kerins D.M., Robertson R.M., and Robertson D. Drugs used for the treatment of myocardial ischemia. In: Hardman J.G., Limbird L.E., and Gilman A.G. (Eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. (2001), McGraw-Hill, New York, NY 843-870
11. MacInnes A., Fairman D.A., Binding P., Rhodes J., Wyatt M.J., Phelan A., Haddock P.S., and Karran E.H. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ. Res. 93 (2003) e26-e32
12. Pepine C.J., and TIDES investigators. Angina pectoris in a contemporary population: characteristics and therapeutic implications. Cardiovasc. Drugs Ther. 12 (1998) 211-216
13. Pepine C.J., Wolff A.A., and on behalf of the Ranolazine Study Group. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Am. J. Cardiol. 84 (1999) 46-50
14. Schwemmer M., Bassenge E., Stoeter M., Hartmann B., Hess U., and Fink B. Potentiation of sildenafil-induced hypotension is minimal with nitrates generating a radical intermediate. J. Cardiovasc. Pharmacol. 38 (2001) 149-155
15. Shryock J.C., Song Y., Wu L., Fraser H., and Belardenelli L. A mechanistic approach to assess the proarrhythmic risk of QT-prolonging drugs in preclinical pharmacologic studies. J. Electrocardiol. 37 (2004) 34-39 (Suppl)
16. Song Y., Shryock J., Wu L., and Belardinelli L. Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes. J. Cardiovasc. Pharmacol. 44 (2004) 192-199
17. Thames M.D., Eastham C.L., and Marcus M.L. Baroreflex control of heart interval in conscious renal hypertensive dogs. Am. J. Physiol. 241 (1981) H332-H336
18. Wang J., Zhao G., Shen W., Ochoa M., Moore D., Hubbard J.W., and Hintze H.H. Effects of an orally active NO-releasing agent, CAS 936, and its active metabolite, 3745, on cardiac and coronary dynamics in normal conscious dogs and after pacing-induced heart failure. J. Cardiovasc. Pharmacol. 22 Suppl 7 (1993) S51-S58
19. Yoo K.Y., Kim H.S., Moon J.D., and Lee J.U. Sildenafil (Viagra) augments sodium nitroprusside-induced but not nitroglycerin-induced hypotension in dogs. Anesth. Analg. 94 (2002) 1505-1509
20. Zoma W.D., Baker R.S., and Clark K.E. Effects of combined use of sildenafil citrate (Viagra) and 17-β-estradiol on ovine coronary and uterine hemodynamics. Am. J. Obstet. Gynecol. 190 (2004) 1291-1297